Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
… -kinase inhibitor erlotinib has … the phase 3, placebo-controlled Sequential Tarceva in
Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy …
Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy …
Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: A multicenter phase 2 trial
S Miyamoto, K Azuma, H Ishii, A Bessho… - JAMA …, 2020 - jamanetwork.com
… Based on the rationales, we hypothesized that low-dose erlotinib would be safe and …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
… A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line
management of advanced non–small-cell lung cancer (NSCLC) patients with a performance …
management of advanced non–small-cell lung cancer (NSCLC) patients with a performance …
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
YY Janjigian, CG Azzoli, LM Krug, LK Pereira… - Clinical cancer …, 2011 - AACR
… erlotinib were rash, fatigue, and hypomagnesemia. The recommended phase II dose identified
was cetuximab 500 mg/m 2 every 2 … results of a trial combining erlotinib and cetuximab in …
was cetuximab 500 mg/m 2 every 2 … results of a trial combining erlotinib and cetuximab in …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
… randomized studies that investigated erlotinib or gefitinib in … a phase II study of single-agent
erlotinib as first-line therapy … study to identify patients who benefited most from treatment. …
erlotinib as first-line therapy … study to identify patients who benefited most from treatment. …
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non–small-cell lung cancer
DR Spigel, HA Burris III, FA Greco… - Journal of clinical …, 2011 - ascopubs.org
… NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial.
… to patients with relapsed NSCLC in a multicenter phase II trial. Fifty-nine percent of patients …
… to patients with relapsed NSCLC in a multicenter phase II trial. Fifty-nine percent of patients …
SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
… 2 during erlotinib treatment and 22 after stopping erlotinib with a median time to recurrence
of 12 months after stopping erlotinib. … -treated with erlotinib with 10 pts remaining on erlotinib, …
of 12 months after stopping erlotinib. … -treated with erlotinib with 10 pts remaining on erlotinib, …
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
D Soulieres, NN Senzer, EE Vokes… - Journal of clinical …, 2004 - ascopubs.org
… the results from phase II trials of erlotinib in other disease sites, [18] and from other EGFR-targeted
therapies, [17,19] clinical outcome of erlotinib in the current study correlated with the …
therapies, [17,19] clinical outcome of erlotinib in the current study correlated with the …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
TSK Mok, YL Wu, CJ Yu, C Zhou, YM Chen… - Journal of Clinical …, 2009 - ascopubs.org
… contribute to the benefit observed with sequential erlotinib in this study. Indeed, two patients
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …
… a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study
SJ Lubner, MR Mahoney, JL Kolesar… - Journal of Clinical …, 2010 - ascopubs.org
… bevacizumab and erlotinib may be synergistic in this regard. This study reports the results of
a multi-institution phase II trial of bevacizumab and erlotinib combination therapy for patients …
a multi-institution phase II trial of bevacizumab and erlotinib combination therapy for patients …
相关搜索
- adjuvant erlotinib multicenter phase ii trial
- daily erlotinib multicenter phase ii trial
- prospective multicentre phase ii trial
- multicenter phase 2 trial egfr mutation
- gemcitabine capecitabine multicenter phase ii study
- cell cancer multicenter phase ii study
- phase ii study temsirolimus and erlotinib
- bevacizumab plus erlotinib phase 2 study
- phase ii trial erlotinib in patients
- randomised phase 2 trial
- combination with bortezomib phase 2 study
- biweekly bevacizumab multicenter phase ii trial
- tract cancer multicenter phase ii study
- phase ii study erlotinib monotherapy
- phase ii study frontline treatment
- phase ii trial growth factor receptor